ShareValue scores for 300294.SHE: Valuation 65, Quality 20, Growth 6, Health 44.

300294.SHE
SZSE

China Resources Boya Bio pharmaceutical Group Co Ltd

CN¥15.60(+1.30%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

4% to 16%
Valuation
65
Fair Value
Price vs Value
Quality
20
Weak
Business Strength
Growth
6
Weak
Revenue & Earnings
Health
44
Moderate
Financial Stability
Momentum
26
Bearish
Price Trend

Company Details

About

China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the research, development, production, and sale of blood products in China. It offers blood products, such as human serum albumin; human, intravenous, freeze-dried intravenous, hepatitis B, tetanus, and rabies immunoglobulin; and human fibrinogen, prothrombin complex, and coagulation factor VIII. The company also provides compound bone peptide, oxytocin, heparin sodium injection, posterior pituitary, and carboprost tromethamine injection. In addition, it engages in research, development, production, and sales of anti-infective, diabetes, and cardiovascular drugs. The company was formerly known as Boya Bio-pharmaceutical Group Co., Ltd. and changed its name to China Resources Boya Bio-pharmaceutical Group Co.,Ltd. The company was founded in 1993 and is based in Fuzhou, China.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026